Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Next Previous
Trial Profile

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Erlotinib (Primary) ; Everolimus (Primary)
  • Indications Diffuse intrinsic pontine glioma; Glioma
  • Focus Therapeutic Use
  • Acronyms BIOMEDE

    • Most Recent Events

    • 06 Jun 2023 Primary endpoint (Overall survival) has not been met according to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2023 Results (n=233) comparing three targeted therapies (erlotinib, everolimus and dasatinib) in combination with 54 Gy radiotherapy, in newly diagnosed patients with DIPG presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 14 Feb 2019 Planned number of patients changed from 250 to 315.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top